- SERVICES & INTELLIGENCE DATABASE

Expert-led intelligence and strategic advisory, powered by proprietary Valiant data and specialist expertise.

Alongside the VIS Platform, we help organizations decide where to invest or partner, which AI solutions merit evaluation, what evidence and funding pathways they need, and where adoption is actually happening.

Intelligence and advisory services for healthcare AI decisions

- HTA, REIMBURSEMENT AND HEALTH-SYSTEM INTELLIGENCE

150+ AI HTA assessments

350+ vendors represented in HTA and reimbursement records

30+ HTA bodies monitored

26 health systems in the AI Maturity Index

- HEALTHCARE AI MARKET INTELLIGENCE

10+ years of longitudinal market tracking

8,000+ healthcare AI vendors tracked

9,000+ AI products mapped

Intelligence base as of October 2026.

Our advisory work combines this proprietary intelligence, the VIS Platform and specialist interpretation, so time goes into your question rather than rebuilding the market picture.

- WHAT WE DELIVER

Six areas, each available on its own, combined or in a workshops and experts sessions

Market and competitive intelligence

Who is active in a clinical area, how crowded each segment is, and which vendors entered, scaled or disappeared over the past decade.

01

TYPICAL OUTPUTS

AI landscape for a clinical area · Competitive density and white-space analysis · Market history

AI strategy, partnerships and due diligence

Where to invest, whether to build, partner or buy, and which AI companies have a credible route to value and strategic fit. Strategic and evidence diligence, not financial, legal, technical or regulatory.

For MedTech, pharma, healthcare AI companies and advisory firms

02

TYPICAL OUTPUTS

Build/partner/buy analysis · Opportunity prioritization map · Partner shortlist and strategic due diligence

For MedTech, pharma, advisory and transaction teams

Clinical AI landscapes and evidence profiles

Which solutions address a defined clinical need, how their evidence compares and what remains uncertain. No paid product placement, no sponsored rankings.

03

TYPICAL OUTPUTS

Clinical AI landscape and shortlist · Comparative evidence profile of three to six products

For hospitals, clinical departments and innovation teams

Evidence, HTA and reimbursement

What a product needs to be assessed, funded and adopted in priority markets: evidence requirements, HTA precedents, funding routes and the gaps to close first.

04

TYPICAL OUTPUTS

Market access and adoption readiness assessment · Evidence, access and adoption strategy · Country pathway map

For MedTech, pharma and healthcare AI companies

Real-world adoption and value

Where a technology is documented in routine or multi-site use rather than pilots, what value has been reported, and what still needs local validation.

05

TYPICAL OUTPUTS

Real-world adoption and value profile · Adoption and scale evidence map

For hospitals, health systems, programs and advisory firms

06

Health-system intelligence

How comparable health systems assess and fund AI, and whether evidence, assessment, funding or adoption is holding promising technologies back.

TYPICAL OUTPUTS

Cross-country AI evaluation and funding benchmark · Evidence, funding and adoption gap analysis

For ministries, payers, HTA bodies and national or regional programs

From intelligence to shared understanding and action

Expert-led sessions built around your team's real questions, combining specialist knowledge with Valiant market, evidence, HTA and reimbursement intelligence. Commissioned on their own or as part of a wider engagement.

Executive briefings · Interactive team workshops · Multi-stakeholder roundtables

Workshops address the regulatory landscape and its implications; they are not regulatory or legal advice.

- HOW ENGAGEMENTS WORK

Scoped to the question, not to a fixed product

Focused intelligence

One defined question, individually scoped, with an executive brief, structured evidence tables and full source references. Selected analyses can be delivered in 10-15 working days, depending on the question and the evidence required.

Strategic engagement

For broader questions, typically structured around understand, analyze, prioritize and decide over roughly twelve weeks, ending in recommendations and a roadmap.

Embedded and ongoing support

A specialist workstream inside a consulting engagement, white-label intelligence, program support, or recurring updates on selected technologies and markets.

Our services do not replace clinical governance, technical or cybersecurity assessment, procurement processes or regulatory submissions.

Start with the question

Tell us what you need to decide. We will show what our intelligence already covers, where deeper analysis is needed, and what can be delivered within your timeline.

info@valiant-health.ai